STOCKHOLM – October 26, 2022
Inify Laboratories, a fully integrated digital ultramodern laboratory services within pathology that provides cancer diagnostics, is advancing towards opening of the company’s new laboratory, situated on Campus Solna close to Karolinska Institutet in Stockholm.
“In an impressively short time, we have built a simulation lab where we further improve, test and verify our development work, ensuring that it fits well into the upcoming production environment,” says CEO Fredrik Palm at Inify Laboratories.
The system has an optimized and standardized workflow for pathological prostate diagnostics with statistical process control. Anything from hardware/software connectivity to advanced AI predictions and workflow improvements can be tested in the simulation laboratory.
Positive feedback from prospective customers
The company is in close dialogue with prospective customers, including private and public healthcare providers.
“The interest and feedback remain very positive – due to both the urgent need and the fact that we create a unique, specialized concept that can take diagnostic services within prostate cancer to a new level in terms of productivity, quality and predictability,” says Palm.
Recruitment of skilled personnel is also progressing as planned, including that of Dr. Claes Lindh, the company’s new Chief Medical Officer (CMO) as of September.
“What attracted me to Inify Laboratories was the opportunity to meet the demands of prostate cancer diagnostics in a new way, a digital diagnostic approach for the 21st century,” says Lindh.
Recruitment processes for several open positions within R&D and laboratory personnel are ongoing, and the company expects to complete them before the end of the year.
With all parts of the company moving forward according to plan, and a growing, dedicated team with full focus on their target, the future is looking bright.
“This progress, paired with the positive response from customers, reinforces our ever-growing optimism regarding a successful market entrance and subsequent growth”, says Palm.
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.